Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company dedicated to developing novel cancer therapies. Leveraging their proprietary PLK1 inhibition technology, Cardiff Oncology focuses on creating innovative treatments for various cancers with significant unmet medical needs.
Cardiff Oncology's lead therapeutic asset is onvansertib, a highly selective Polo-like kinase 1 (PLK1) inhibitor. This investigational drug is currently being evaluated in clinical trials for its effectiveness in treating multiple types of cancer, including RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
Recent achievements include promising clinical data for onvansertib monotherapy and combination therapy in mPDAC and SCLC trials. The mPDAC Phase 2 trial reported a 19% objective response rate (ORR) and a median progression-free survival (mPFS) of 5.0 months, compared to historical controls with an ORR of 7.7% and mPFS of 3.1 months. In SCLC, onvansertib monotherapy has demonstrated encouraging single-agent activity.
Cardiff Oncology continues to expand its clinical programs and research partnerships. They announced a first-line trial in mPDAC in collaboration with Oregon Health & Science University (OHSU) Knight Cancer Institute, exploring both monotherapy and combination therapy with standard care. Furthermore, the company highlights an ongoing Phase 1b/2 study for KRAS-mutated mCRC, which has shown a favorable safety profile and promising efficacy results.
Financially, Cardiff Oncology reported a strong cash position with approximately $81.4 million in cash, cash equivalents, and short-term investments as of September 30, 2023. Their operational strategy is supported by partnerships and ongoing research endeavors, which are projected to fund operations into 2025.
The company's forward-looking initiatives include the advancement of their lead program in RAS-mutated mCRC to the first-line setting and continuous exploration of onvansertib's potential in various cancer treatments. Investors and stakeholders can stay updated through regular business updates and conference calls hosted by Cardiff Oncology.
Cardiff Oncology, a clinical-stage oncology company, announced updated data on its KRAS-mutated metastatic colorectal cancer program will be presented at the ASCO-GI from January 20-22, 2022, in San Francisco. The poster presentation titled "A phase 1b/2 trial of the PLK1 inhibitor onvansertib..." will showcase findings related to onvansertib in combination with FOLFIRI-bev for treating KRAS-mutated metastatic colorectal cancer. The abstract will be published on January 18, 2022, and is part of Poster Session C on January 22, 2022.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the grant of non-qualified stock options for 200,112 shares to two new employees on December 2, 2021. The options, set at an exercise price of $5.46 per share, will vest over four years, with 25% vesting after one year. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent in the oncology-focused firm. Cardiff is developing precision medicine for high-need cancer indications, including KRAS-mutated colorectal cancer and pancreatic cancer.
Cardiff Oncology (Nasdaq: CRDF) announced a $15 million equity investment from Pfizer (NYSE: PFE) to support its clinical programs for KRAS-mutated cancers, including colorectal and pancreatic cancer. Pfizer acquired 2.4 million shares at $6.22 each as part of its Breakthrough Growth Initiative. This collaboration aims to enhance Cardiff's efforts in developing onvansertib, a PLK1 inhibitor, alongside leveraging data from their clinical trials. Pfizer's VP, Adam Schayowitz, is set to join Cardiff's Scientific Advisory Board to further assist in innovative cancer therapies.
Cardiff Oncology (Nasdaq: CRDF) announced participation in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference from November 16 to December 2, 2021. Key presentations will focus on their precision medicine treatments for cancer, particularly targeting unmet needs in KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. These presentations will be available on-demand, with specific availability dates outlined for each conference.
Cardiff Oncology (Nasdaq: CRDF) reported significant progress in its Phase 1b/2 trial for KRAS-mutated colorectal cancer, showing a 37% objective response rate (ORR) with onvansertib combined with standard treatment. The median progression-free survival (mPFS) reached 9.4 months, surpassing historical controls. The company strengthened its leadership team with new appointments and ended Q3 2021 with approximately $134 million in cash, despite increased operating expenses of $7.1 million, mainly due to clinical development efforts.
Cardiff Oncology (CRDF) reported promising results from its Phase 1b/2 trial of onvansertib combined with FOLFIRI/bevacizumab for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). Of the 19 patients treated at the recommended dose, 42% achieved a partial response, significantly exceeding the historical 5-13% response rates. The median progression-free survival (mPFS) was 9.4 months, higher than the typical 4.5-5.7 months. The drug was well tolerated, with manageable adverse events. Further updates are expected as the trial progresses.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology firm, announced its participation in two upcoming virtual investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021. During these events, CEO Mark Erlander and CFO James Levine will engage in presentations and one-on-one meetings. Cardiff is focused on developing onvansertib, a novel cancer treatment targeting unmet medical needs, particularly in KRAS-mutated cancers.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology company, will host a virtual KOL event on September 8, 2021, from 4:00 - 5:00 PM ET. The event will showcase new data from its Phase 1b/2 trial evaluating onvansertib in combination with FOLFIRI/bevacizumab for patients with KRAS-mutated colorectal cancer. Key speakers include Heinz-Josef Lenz and Afsaneh Barzi, with a Q&A session to follow. This event aims to inform analysts and investors about advancements in cancer treatment options.
Cardiff Oncology (Nasdaq: CRDF) reported significant advancements in its clinical development of onvansertib for difficult-to-treat cancers, including KRAS-mutated colorectal cancer and pancreatic cancer, during Q2 2021. CEO Mark Erlander highlighted crucial milestones and leadership changes, including the appointment of a new CMO and CFO. The company initiated a Phase 2 trial for metastatic pancreatic cancer and presented positive data for its colorectal cancer program, indicating enhanced patient outcomes. Financially, Cardiff holds approximately $140 million in cash, with operating expenses rising to $7 million due to clinical activities.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the appointments of Katherine L. Ruffner, M.D. as CMO and James E. Levine as CFO on July 12, 2021. Dr. Ruffner will lead clinical programs and pipeline expansion for onvansertib, aimed at treating cancers with critical medical needs. Mr. Levine will focus on financial strategy and business development. Both bring extensive experience in their fields, aligning with the company's growth strategy around upcoming clinical milestones. The Board approved stock options for the new executives as part of their inducement to join.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
What is Cardiff Oncology's primary focus?
What is onvansertib?
Which cancers is Cardiff Oncology targeting with onvansertib?
What are the recent clinical achievements of Cardiff Oncology?
What is the financial condition of Cardiff Oncology?
What are the upcoming milestones for Cardiff Oncology?
How can investors stay updated about Cardiff Oncology?
What partnerships does Cardiff Oncology have?
What is the significance of PLK1 in cancer treatment?
Where can more information about Cardiff Oncology be found?
